33620 Results

People

  1. Ladanyi
    Ladanyi
  2. Giralt
    Giralt
  3. Motzer
    Motzer
  4. Reuter
    Reuter
  5. Perales
    Perales
  6. Scher
    Scher
  7. Zelenetz
    Zelenetz
  8. Berger
    Berger
  9. Al-Ahmadie
    Al-Ahmadie
  10. O'Reilly
    O'Reilly

Groups

  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)
  7. Department of Pathology and Laboratory Medicine (5172)
  8. Surgery (4871)
  9. Sloan Kettering Institute Faculty (3826)
  10. Sloan Kettering Institute Postdocs (3612)
  1. "Meeting abstract"
Formats
  1. Meeting Abstract (33620)
Groups
  1. Department of Medicine (15822)
  2. Solid Tumor Oncology Division (9435)
  3. GSK Faculty (7076)
  4. Hematologic Malignancies, Division of (6210)
  5. Center for Hematologic Malignancies (6017)
  6. Survivorship Research (5192)

More Groups

People
  1. Marc Ladanyi (641)
  2. Sergio Giralt (632)
  3. Robert Motzer (574)
  4. Victor Reuter (568)
  5. Miguel-Angel Perales (482)
  6. Howard Scher (463)

More People

Years
  1. 2025 (295)
  2. 2024 (1694)
  3. 2023 (1954)
  4. 2022 (2196)
  5. 2021 (1731)
  6. 2020 (1901)

More Years

Publications
  1. Journal of Clinical Oncology (6252)
  2. Blood (3939)
  3. Laboratory Investigation (1846)
  4. Cancer Research (1822)
  5. International Journal of Radiation Oncology, Biology, Physics (1643)
  6. Modern Pathology (1494)

More Publications

Publishers
  1. American Society of Clinical Oncology (6251)
  2. Elsevier Inc. (4694)
  3. American Society of Hematology (3939)
  4. American Association for Cancer Research (3045)
  5. Nature Publishing Group (2151)
  6. Oxford University Press (2096)

More Publishers

Results (33620)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Obinutuzumab (G)-atezolizumab (atezo)-lenalidomide (len) for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL): Final analysis of a phase Ib/II trial
    Meeting Abstract

    Ghosh, N.; Salles, G. A.; Lossos, I. S.; Palomba, M. L.; Mehta, A.; Casasnovas, O.; Stevens, D. A.; Katakam, S.; Knapp, A.; Nielsen, T.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed/refractory Ewing sarcoma
    Meeting Abstract

    Reed, D. R.; Chawla, S. P.; Setty, B.; Mascarenhas, L.; Meyers, P. A.; Metts, J.; Harrison, D. J.; Loeb, D.; Crompton, B. D.; Wages, D. S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Mobocertinib (TAK-788) in EGFR exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study
    Meeting Abstract

    Ramalingam, S. S.; Zhou, C.; Kim, T. M.; Kim, S. W.; Yang, J. C. H.; Riely, G. J.; Mekhail, T.; Nguyen, D.; Campelo, M. R. G.; Felip, E.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study
    Meeting Abstract

    Mathews, C. A.; Simpkins, F.; Cadoo, K. A.; Liu, Y. L.; Provencher, D. M.; McCormick, C.; ElNaggar, A.; Altman, A. D.; Gilbert, L.; Black, D.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with MET amplification (METamp)
    Meeting Abstract

    Le, X.; Paz-Ares, L. G.; Van Meerbeeck, J.; Viteri, S.; Galvez, C. C.; Baz, D. V.; Kim, Y. C.; Kang, J. H.; Schumacher, K. M.; Karachaliou, N.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve
    Meeting Abstract

    Chia, S. K. L.; Ruiz-Borrego, M.; Drullinsky, P.; Juric, D.; Bachelot, T.; Rugo, H. S.; Ciruelos, E. M.; Lerebours, F.; Prat, A.; Akdere, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Phase 2 trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001
    Meeting Abstract

    Peters, K. B.; Villano, J. L.; Butowski, N. A.; Cohen, A. L.; Mendez, J. S.; Giglio, P.; Zhang, C.; Raza, S.; McGranahan, T.; Lobbous, M.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer
    Meeting Abstract

    Ricciuti, B.; Arbour, K. C.; Alessi, J. V. M.; Mahadevan, N.; Lindsay, J.; Sinha, R.; Vokes, N. I.; Recondo, G.; Lamberti, G.; Rizvi, H.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Selpercatinib efficacy and safety in patients with RET-altered thyroid cancer: A clinical trial update
    Meeting Abstract

    Sherman, E. J.; Wirth, L. J.; Shah, M. H.; Cabanillas, M. E.; Robinson, B.; Laskin, J. J.; Kroiss, M.; Subbiah, V.; Drilon, A. E.; Wright, J.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy of selpercatinib after prior systemic therapy in patients with RET mutant medullary thyroid cancer
    Meeting Abstract

    Wirth, L. J.; Sherman, E. J.; Weiler, D.; Cabanillas, M. E.; Robinson, B.; Italiano, A.; Laskin, J. J.; Subbiah, V.; Drilon, A. E.; Soldatenkova, V.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save